TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8561836

Group type: EXPERIMENTAL
Intervention: 15 mg cycloserine
Number of subjects: 410

Group type: COMPARATOR
Intervention: 5 mg cycloserine
Number of subjects: 410

Group type: COMPARATOR
Intervention: 50 mg cycloserine
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 2230895

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) (n = 193)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 391

Group type: COMPARATOR
Intervention: No adjuvant therapy (Control) (n = 198)
Number of subjects: 391
Study: 380838

Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20‐511, 'Zaditen', Sandoz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31505724

Group type: EXPERIMENTAL
Intervention: Mixed-rod group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double-rod group
Number of subjects: 16
Study: 26821181

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 0
Study: 26262795

Group type: EXPERIMENTAL
Intervention: Testosterone administration (7.5 g of 1% testosterone gel daily for 3 years)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo (gel packets daily for 3 years)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 23595205

Group type: EXPERIMENTAL
Intervention: BA+SB
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: BA
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SB
Number of subjects: 37

Group type: COMPARATOR
Intervention: PL+PL
Number of subjects: 37
Study: 20533282

Group type: EXPERIMENTAL
Intervention: Dietary vitamin D intake (highest vs lowest quartile)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels (highest vs lowest quartile)
Number of subjects: 540
Study: 19210644

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (6 mg/kg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ketotifen fumarate (0.06 mg/kg daily)
Number of subjects: 53
Study: 16966191

Group type: EXPERIMENTAL
Intervention: Drinks per drinking day (DDD)
Number of subjects: 0
Study: 15034704

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 7 days
Number of subjects: 12
Study: 11142548

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for generalized anxiety disorder (GAD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 26
Study: 9284519

Group type: EXPERIMENTAL
Intervention: Amiloride (100 microns) delivered for 5 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (before amiloride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-amiloride response
Number of subjects: 20
Study: 8222103

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 8261
Study: 3520798

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 371

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 371
Study: 31059421

Group type: EXPERIMENTAL
Intervention: AR-guided binocular
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AR-guided monocular
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naked-eye tests (both monocular and binocular)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AR tests
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monocular tests
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Binocular tests
Number of subjects: 20
Study: 28579159

Group type: EXPERIMENTAL
Intervention: Physiological warm-up (semi-occluded exercises)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional warm-up (open vowel [a:])
Number of subjects: 30
Study: 27143594

Group type: EXPERIMENTAL
Intervention: RYR-NS (red yeast rice, grape-seed, niacinamide, and folic acid)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 24838406

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n=201)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo (n=207)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Number of subjects: 408
Study: 21974926

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation program using a self-help manual
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 20370938

Group type: EXPERIMENTAL
Intervention: Dietary group (DG) receiving daily 1200 mg Ca and 7.5 microg vitamin D3 for the first 12 months, then 1200 mg Ca and 22.5 microg vitamin D3 for the next 18 months through fortified dairy products
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dietary group (DG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CG) receiving neither counselling nor dairy products
Number of subjects: 66
Study: 18840700

Group type: EXPERIMENTAL
Intervention: Stuttering treatment efficacy research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-step, semi-automated, Internet-based method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-item checklist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing taxonomy with 136-item checklist
Number of subjects: 0
Study: 16365207

Group type: EXPERIMENTAL
Intervention: CABG with cardiopulmonary bypass (CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Off‐pump (OPCAB) grafting
Number of subjects: 20
Study: 12225715

Group type: EXPERIMENTAL
Intervention: Infarct angiography
Number of subjects: 548

Group type: COMPARATOR
Intervention: Noninfarct angiography
Number of subjects: 548
Study: 10217232

Group type: EXPERIMENTAL
Intervention: rBPI21 (4 mg x kg(‐1) x d(‐1) for 2 consecutive days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo (equivalent volume by continuous infusion)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 7884138

Group type: EXPERIMENTAL
Intervention: New ergonomic stand magnifiers
Number of subjects: 39

Group type: COMPARATOR
Intervention: Commercial stand magnifier
Number of subjects: 39
Study: 2223340

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 3
Study: 80219

Group type: EXPERIMENTAL
Intervention: Perhexiline (300 to 400 mg per day)
Number of subjects: 20
Study: 30205115

Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing (CYP2C9, VKORC1, and CYP4F2)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Clinical-guided warfarin dosing
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 201
Study: 27634581

Group type: EXPERIMENTAL
Intervention: Flash sensor‐based glucose monitoring
Number of subjects: 328

Group type: COMPARATOR
Intervention: Self‐monitoring of blood glucose with capillary strips
Number of subjects: 328
Study: 24890623

Group type: EXPERIMENTAL
Intervention: 2L-PEG preparations
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: 2-glasses solutions
Number of subjects: 599

Group type: COMPARATOR
Intervention: 4L-PEG preparations
Number of subjects: 599
Study: 22284040

Group type: EXPERIMENTAL
Intervention: CAG + β‐RT
Number of subjects: 108

Group type: COMPARATOR
Intervention: CAG
Number of subjects: 108
Study: 20206571

Group type: EXPERIMENTAL
Intervention: Pulsed dose-rate (PDR) brachytherapy with optimized dose distribution
Number of subjects: 463

Group type: COMPARATOR
Intervention: Non-optimized PDR brachytherapy
Number of subjects: 463

Group type: COMPARATOR
Intervention: Iridium wires (traditional treatment)
Number of subjects: 463
Study: 18608313

Group type: EXPERIMENTAL
Intervention: Cognitive therapy combined with imipramine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure treatment combined with imipramine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cognitive treatment combined with imipramine
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Supportive therapy combined with imipramine
Number of subjects: 137

Group type: COMPARATOR
Intervention: Cognitive therapy combined with placebo
Number of subjects: 137

Group type: COMPARATOR
Intervention: Graded in vivo exposure treatment combined with placebo
Number of subjects: 137

Group type: COMPARATOR
Intervention: Cognitive treatment combined with placebo
Number of subjects: 137

Group type: COMPARATOR
Intervention: Supportive therapy combined with placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 15740994

Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relatives' Group
Number of subjects: 0
Study: 12635365

Group type: EXPERIMENTAL
Intervention: HCV serotype testing using an indirect ELISA (Murex HCV Serotypes 1‐6 Assay)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCV serotype testing
Number of subjects: 22
Study: 10659548

Group type: EXPERIMENTAL
Intervention: 300 mg levofloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 mg levofloxacin
Number of subjects: 12
Study: 8680689

Group type: EXPERIMENTAL
Intervention: L-NAME (nonselective NOS inhibitor)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aminoguanidine (selective inhibitor of inducible NOS)
Number of subjects: 15
Study: 1725036

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 35

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 35
Study: 6851655

Group type: EXPERIMENTAL
Intervention: Amcinonide ointment 0.1 percent twice a day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05 percent three times a day
Number of subjects: 39
Study: 31792646

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 30763138

Group type: EXPERIMENTAL
Intervention: Glass Infiltration (GI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sol-Gel Silica Infiltration (SG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 150
Study: 28373993

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day (group A, n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (group B, n = 32)
Number of subjects: 63
Study: 26071673

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low-dose combined oral contraceptive (COC)
Number of subjects: 62
Study: 23025591

Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.10% (D1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.25% (D2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.50% (D3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (D4; no A. aspera supplementation)
Number of subjects: 0
Study: 20456821

Group type: EXPERIMENTAL
Intervention: Deliberate decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intuitive decision making
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distracted decision making
Number of subjects: 0
Study: 18382064

Group type: EXPERIMENTAL
Intervention: Group BK3 (butorphanol 2 microg/(kg x h) mixed with ketamine 120 microg/(kg x h))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group BK2 (butorphanol 2 microg/(kg x h) mixed with ketamine 90 microg/(kg x h))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group BK1 (butorphanol 2 microg/(kg x h) mixed with ketamine 60 microg/(kg x h))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B (butorphanol 3 microg/(kg x h))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 15692755

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 251

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 251
Study: 12010096

Group type: EXPERIMENTAL
Intervention: Enhanced power Doppler ultrasound
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unenhanced color Doppler ultrasound
Number of subjects: 53

Group type: COMPARATOR
Intervention: Biphasic computed tomography (CT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ultrasound (with or without contrast)
Number of subjects: 53
Study: 10090432

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg oral loading dose followed by 200 mg/d for 10 days)
Number of subjects: 2916

Group type: COMPARATOR
Intervention: Comparator therapies (erythromycin, cefaclor, ofloxacin, clarithromycin, and ciprofloxacin)
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 2916

Group type: COMPARATOR
Intervention: Comparator therapies
Number of subjects: 2916
Study: 7727835

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate preparation under occlusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Corticoid‐free cream under occlusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment and occlusion (aluminium chamber)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment and no occlusion
Number of subjects: 20
Study: 2029832

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6873608

Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg at 5 h and at 30 min before the meal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31725909

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0
Study: 29718418

Group type: EXPERIMENTAL
Intervention: Dry needling + exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 61
Study: 27385022

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg) with fixed dose of diuretics
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tolvaptan (15 mg) with half-dose of diuretics
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (Tolvaptan with fixed dose and half-dose of diuretics)
Number of subjects: 44
Study: 26912557

Group type: EXPERIMENTAL
Intervention: Radium-223 plus standard of care (SOC)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 921
Study: 24680848

Group type: EXPERIMENTAL
Intervention: Condition 1: preconditioning with cathodal tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Condition 2: preconditioning with anodal tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Condition 3: sham tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15

Group type: COMPARATOR
Intervention: Condition 4: sham tDCS over the left M1 followed by sham rTMS over the right M1
Number of subjects: 15
Study: 18828899

Group type: EXPERIMENTAL
Intervention: IPTi-1 (sulphadoxine-pyrimethamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPTi-2 (sulphadoxine-pyrimethamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPTi-3 (sulphadoxine-pyrimethamine)
Number of subjects: 0
Study: 15194017

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 10 mg
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 20 mg
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 40 mg
Number of subjects: 710

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 710
Study: 11001754

Group type: EXPERIMENTAL
Intervention: Endurance trained
Number of subjects: 29
Study: 9311407

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 2.1 ml/h (low rate group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 6.3 ml/h (high rate group)
Number of subjects: 24
Study: 7506178

Group type: EXPERIMENTAL
Intervention: Nimesulide 50 mg/dose
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lysine-acetylsalicylate 720 mg/dose
Number of subjects: 70
Study: 2882339

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (subcutaneous calcium heparin, 12,500 IU daily)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control group (usual therapy)
Number of subjects: 728
Study: 30932953

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 3438

Group type: COMPARATOR
Intervention: Deferred ART initiation
Number of subjects: 3438
Study: 28581346

Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral therapy group program - 'Recapture Life'
Number of subjects: 39
Study: 26702595

Group type: COMPARATOR
Intervention: Matched hydration (MHG)
Number of subjects: 133
Study: 25080942

Group type: EXPERIMENTAL
Intervention: Programmatic preconception care (PCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic antenatal risk assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (municipalities not receiving interventions)
Number of subjects: 0
Study: 22836851

Group type: EXPERIMENTAL
Intervention: SNAPPS technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Customary presentations
Number of subjects: 60
Study: 19738402

Group type: EXPERIMENTAL
Intervention: ERASE Stress Sri Lanka (ES-SL)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Waiting list (WL) religious class
Number of subjects: 166
Study: 17368248

Group type: EXPERIMENTAL
Intervention: Local intracervical anesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Combined local and paracervical anesthesia
Number of subjects: 84
Study: 15548777

Group type: EXPERIMENTAL
Intervention: Continuous 2-MHz transcranial Doppler ultrasonography
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 11672452

Group type: EXPERIMENTAL
Intervention: Home-based unsupervised exercise training programme of moderate intensity
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-exercising control period
Number of subjects: 9
Study: 9218069

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. (OME20)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg o.m. (OME10)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d. (RAN)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg weekends (OMEW)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Cox's regression analysis
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Asymptomatic relapse
Number of subjects: 1154
Study: 8034405

Group type: EXPERIMENTAL
Intervention: ComputerLink (nurse-supervised information, decision support, and communication services)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Public communication area (functioned like a support group)
Number of subjects: 26
Study: 3661107

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg i.v.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydergine 0.9 mg i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study: 28728886

Group type: EXPERIMENTAL
Intervention: Supervised group exercises
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 133
Study: 27594379

Group type: EXPERIMENTAL
Intervention: Intra-amniotic surfactant (3mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24631589

Group type: COMPARATOR
Intervention: LY545694 (2 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY545694 (3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY545694 (all doses)
Number of subjects: 0
Study: 23870501

Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Off site simulation (OSS)
Number of subjects: 100
Study: 19930764

Group type: EXPERIMENTAL
Intervention: 5-6 g beta-glucan
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 8-9 g beta-glucan
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (2 MJ energy-deficit diet without beta-glucan)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 66
Study: 17512158

Group type: EXPERIMENTAL
Intervention: CRA plus vouchers
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 43
Study: 16914415

Group type: EXPERIMENTAL
Intervention: Intracutaneous closure suture alone (Group A1)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Subcutaneous suture line (Group A2)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Group A (combined Group A1 and A2)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (Group B, operated by surgical residents)
Number of subjects: 243
Study: 14696461

Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a (4.5 million units daily for 16 weeks) plus Lamivudine (100 mg daily starting from week 5 for 48 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily for 48 weeks)
Number of subjects: 61
Study: 10809458

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (clinical nurse specialists for symptom control and communication facilitation)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 767
Study: 8649661

Group type: EXPERIMENTAL
Intervention: 0.2 percent chlorhexidine solution applied with an interdental brush
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.1 percent quinine solution (control) applied with an interdental brush
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 0.2 percent chlorhexidine solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.1 percent quinine solution (control)
Number of subjects: 33